Literature DB >> 29427100

X-Linked Spinal and Bulbar Muscular Atrophy: From Clinical Genetic Features and Molecular Pathology to Mechanisms Underlying Disease Toxicity.

Constanza J Cortes1, Albert R La Spada2.   

Abstract

Spinal and Bulbar Muscular Atrophy (SBMA) is an inherited neuromuscular disorder caused by a CAG-polyglutamine (polyQ) repeat expansion in the androgen receptor (AR) gene. Unlike other polyQ diseases, where the function of the native causative protein is unknown, the biology of AR is well understood, and this knowledge has informed our understanding of how native AR function interfaces with polyQ-AR dysfunction. Furthermore, ligand-dependent activation of AR has been linked to SBMA disease pathogenesis, and has led to a thorough study of androgen-mediated effects on polyQ-AR stability, degradation, and post-translational modifications, as well as their roles in the disease process. Transcriptional dysregulation, proteostasis dysfunction, and mitochondrial abnormalities are central to polyQ-AR neurotoxicity, most likely via a 'change-of-function' mechanism. Intriguingly, recent work has demonstrated a principal role for skeletal muscle in SBMA disease pathogenesis, indicating that polyQ-AR toxicity initiates in skeletal muscle and results in secondary motor neuron demise. The existence of robust animal models for SBMA has permitted a variety of preclinical trials, driven by recent discoveries of altered cellular processes, and some of this preclinical work has led to human clinical trials. In this chapter, we review SBMA clinical features and disease biology, discuss our current understanding of the cellular and molecular basis of SBMA pathogenesis, and highlight ongoing efforts toward therapy development.

Entities:  

Keywords:  Androgen receptor; Motor neuron; Polyglutamine; Proteostasis; Skeletal muscle; Transcription

Mesh:

Substances:

Year:  2018        PMID: 29427100     DOI: 10.1007/978-3-319-71779-1_5

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

Review 1.  DNA Damage Repair in Huntington's Disease and Other Neurodegenerative Diseases.

Authors:  T Maiuri; C E Suart; C L K Hung; K J Graham; C A Barba Bazan; R Truant
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

Review 2.  Exploring the Role of Posttranslational Modifications in Spinal and Bulbar Muscular Atrophy.

Authors:  Neha Gogia; Luhan Ni; Victor Olmos; Fatema Haidery; Kimberly Luttik; Janghoo Lim
Journal:  Front Mol Neurosci       Date:  2022-06-03       Impact factor: 6.261

Review 3.  Modeling Polyglutamine Expansion Diseases with Induced Pluripotent Stem Cells.

Authors:  Swati Naphade; Kizito-Tshitoko Tshilenge; Lisa M Ellerby
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

4.  Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy.

Authors:  Vittoria Lombardi; Giorgia Querin; Oliver J Ziff; Luca Zampedri; Ilaria Martinelli; Carolin Heller; Martha Foiani; Cinzia Bertolin; Ching-Hua Lu; Bilal Malik; Kezia Allen; Carlo Rinaldi; Henrik Zetterberg; Amanda Heslegrave; Linda Greensmith; Michael Hanna; Gianni Soraru; Andrea Malaspina; Pietro Fratta
Journal:  Neurology       Date:  2019-02-20       Impact factor: 9.910

Review 5.  Advances in Modeling Polyglutamine Diseases Using Genome Editing Tools.

Authors:  Marianna Karwacka; Marta Olejniczak
Journal:  Cells       Date:  2022-02-02       Impact factor: 6.600

Review 6.  A survey of protein interactions and posttranslational modifications that influence the polyglutamine diseases.

Authors:  Sean L Johnson; Wei-Ling Tsou; Matthew V Prifti; Autumn L Harris; Sokol V Todi
Journal:  Front Mol Neurosci       Date:  2022-09-14       Impact factor: 6.261

Review 7.  Polyglutamine Repeats in Viruses.

Authors:  Catherine H Schein
Journal:  Mol Neurobiol       Date:  2018-09-04       Impact factor: 5.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.